Revolution Medicines, Inc. Operating Expenses
Revolution Medicines, Inc. (RVMD) reported Operating Expenses of $505.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Revolution Medicines, Inc. operating expenses for the quarter ending 2026-06-30 was $505.13M, a 90.82% increase year-over-year.
- Revolution Medicines, Inc. operating expenses for the quarter ending 2026-03-31 was $445.22M, a 84.92% increase year-over-year.
- Revolution Medicines, Inc. operating expenses for the quarter ending 2025-12-31 was $361.63M, a 67.18% increase year-over-year.
- Revolution Medicines, Inc. operating expenses for the quarter ending 2025-09-30 was $315.27M, a 79.42% increase year-over-year.
- Revolution Medicines, Inc. operating expenses for fiscal 2025 was $1.18B, a 71.48% increase from fiscal 2024.
- Revolution Medicines, Inc. operating expenses for fiscal 2024 was $689.52M, a 38.25% increase from fiscal 2023.
- Revolution Medicines, Inc. operating expenses for fiscal 2023 was $498.76M, a 69.84% increase from fiscal 2022.
- Revolution Medicines, Inc. operating expenses for fiscal 2022 was $293.66M, a 35.08% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $505.13M 10-Q · filed 2026-08-05 | $950.35M 10-Q · filed 2026-08-05 | $1.31B derived: sum of 3 quarters · filed 2026-08-05 | $1.63B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $445.22M 10-Q · filed 2026-05-06 | $806.85M derived: sum of 2 quarters · filed 2026-05-06 | $1.12B derived: sum of 3 quarters · filed 2026-05-06 | $1.39B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $361.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $676.89M derived: sum of 2 quarters · filed 2026-02-25 | $941.61M derived: sum of 3 quarters · filed 2026-08-05 | $1.18B 10-K · filed 2026-02-25 |
| 2025-09-30 | $315.27M 10-Q · filed 2025-11-05 | $579.98M derived: sum of 2 quarters · filed 2026-08-05 | $820.74M 10-Q · filed 2025-11-05 | $1.04B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $264.71M 10-Q · filed 2026-08-05 | $505.47M 10-Q · filed 2026-08-05 | $721.78M derived: sum of 3 quarters · filed 2026-08-05 | $897.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $240.76M 10-Q · filed 2026-05-06 | $457.07M derived: sum of 2 quarters · filed 2026-05-06 | $632.78M derived: sum of 3 quarters · filed 2026-05-06 | $789.42M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $216.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $392.02M derived: sum of 2 quarters · filed 2026-02-25 | $548.66M derived: sum of 3 quarters · filed 2026-02-25 | $689.52M 10-K · filed 2026-02-25 |
| 2024-09-30 | $175.71M 10-Q · filed 2025-11-05 | $332.36M derived: sum of 2 quarters · filed 2025-11-05 | $473.21M 10-Q · filed 2025-11-05 | $653.94M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $156.64M 10-Q · filed 2025-08-06 | $297.50M 10-Q · filed 2025-08-06 | $478.23M derived: sum of 3 quarters · filed 2026-02-25 | $601.48M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $140.86M 10-Q · filed 2025-05-07 | $321.58M derived: sum of 2 quarters · filed 2026-02-25 | $444.83M derived: sum of 3 quarters · filed 2026-02-25 | $557.45M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $180.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $303.97M derived: sum of 2 quarters · filed 2026-02-25 | $416.59M derived: sum of 3 quarters · filed 2026-02-25 | $498.76M 10-K · filed 2026-02-25 |
| 2023-09-30 | $123.25M 10-Q · filed 2024-11-06 | $235.87M derived: sum of 2 quarters · filed 2024-11-06 | $318.04M 10-Q · filed 2024-11-06 | $395.08M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $112.62M 10-Q · filed 2024-08-07 | $194.79M 10-Q · filed 2024-08-07 | $271.83M derived: sum of 3 quarters · filed 2025-02-26 | $351.72M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $82.17M 10-Q · filed 2024-05-08 | $159.21M derived: sum of 2 quarters · filed 2025-02-26 | $239.10M derived: sum of 3 quarters · filed 2025-02-26 | $310.30M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $77.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $156.93M derived: sum of 2 quarters · filed 2025-02-26 | $228.13M derived: sum of 3 quarters · filed 2025-02-26 | $293.66M 10-K · filed 2025-02-26 |
| 2022-09-30 | $79.89M 10-Q · filed 2023-11-06 | $151.09M derived: sum of 2 quarters · filed 2023-11-06 | $216.62M 10-Q · filed 2023-11-06 | $278.99M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $71.20M 10-Q · filed 2023-08-08 | $136.73M 10-Q · filed 2023-08-08 | $199.10M derived: sum of 3 quarters · filed 2024-02-26 | $253.37M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $65.53M 10-Q · filed 2023-05-08 | $127.90M derived: sum of 2 quarters · filed 2024-02-26 | $182.16M derived: sum of 3 quarters · filed 2024-02-26 | $235.40M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $62.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $116.64M derived: sum of 2 quarters · filed 2024-02-26 | $169.87M derived: sum of 3 quarters · filed 2024-02-26 | $217.40M 10-K · filed 2024-02-26 |
| 2021-09-30 | $54.26M 10-Q · filed 2022-11-07 | $107.50M derived: sum of 2 quarters · filed 2022-11-07 | $155.03M 10-Q · filed 2022-11-07 | $197.86M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $53.23M 10-Q · filed 2022-08-09 | $100.76M 10-Q · filed 2022-08-09 | $143.59M derived: sum of 3 quarters · filed 2023-02-27 | $183.80M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $47.53M 10-Q · filed 2022-05-09 | $90.36M derived: sum of 2 quarters · filed 2023-02-27 | $130.57M derived: sum of 3 quarters · filed 2023-02-27 | $168.58M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $42.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $83.04M derived: sum of 2 quarters · filed 2023-02-27 | $121.05M derived: sum of 3 quarters · filed 2023-02-27 | $153.68M 10-K · filed 2023-02-27 |
| 2020-09-30 | $40.21M 10-Q · filed 2021-11-10 | $78.22M derived: sum of 2 quarters · filed 2021-11-10 | $110.85M 10-Q · filed 2021-11-10 | $142.50M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $38.01M 10-Q · filed 2021-08-11 | $70.64M 10-Q · filed 2021-08-11 | $102.29M derived: sum of 3 quarters · filed 2022-02-28 | $128.35M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $32.63M 10-Q · filed 2021-05-10 | $64.28M derived: sum of 2 quarters · filed 2022-02-28 | $90.34M derived: sum of 3 quarters · filed 2022-02-28 | $113.19M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $31.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $57.72M derived: sum of 2 quarters · filed 2022-02-28 | $80.56M derived: sum of 3 quarters · filed 2022-02-28 | $104.16M 10-K · filed 2022-02-28 |
| 2019-09-30 | $26.07M 10-Q · filed 2020-11-12 | $48.91M derived: sum of 2 quarters · filed 2020-11-12 | $72.51M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $22.84M 10-Q · filed 2020-08-10 | $46.44M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $23.60M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $60.49M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |